New insights into the metabolomic profiles of benign prostatic hyperplasia
In recent years, the metabolomics It has proven to be an innovative tool to better understand thebenign prostatic hyperplasia (BPH). Several recent studies have shown that patients affected by BPH present significant alterations in metabolomic profiles, particularly in compounds involved in the metabolism of amino acids, of the lipids and of the sugars. These metabolic changes reflect the chronic inflammatory state and hormonal changes associated with prostate enlargement. Analyzing samples of urine, blood And seminal fluid, researchers have managed to identify biomarkers that could help in the early diagnosis and in monitoring disease progression.
Metabolomics as a diagnostic tool
One of the most promising developments is the use of metabolomics to distinguish thebenign prostatic hypertrophy from pathologies that can have similar symptoms, such as prostate cancer. Studies conducted with mass spectrometry techniques have highlighted specific metabolomic signatures which allow for greater diagnostic accuracy. This approach could reduce the use of invasive tests, such as biopsy, while improving theaccuracy in differential diagnosis. Furthermore, thanks to the identification of specific metabolites, it is possible to monitor the effectiveness of drug treatments and personalize therapies based on the patient’s metabolomic response.
Towards personalized therapies
Metabolomics is not only useful in diagnosis, but also in the development of new therapeutic strategies. Some studies have shown that drug administration can modify the metabolomic profiles in patients with benign prostatic hypertrophy, suggesting a potential for the creation of targeted therapies. In the future, thanks to the detailed understanding of the metabolomic pathways involved in thebenign prostatic hypertrophy, it will be possible to intervene more specifically, reducing side effects and increasing the effectiveness of the treatment. This represents an important step towards a precision medicine, even in areas that have been considered little explored so far, such asbenign prostatic hypertrophy.
For further information:
- Zniber M, Lamminen T, Taimen P, Boström PJ, Huynh TP. 1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia. Heliyon. 2024 Mar 31;10(7):e28949.
- Pérez-Rambla C, Puchades-Carrasco L, García-Flores M, Rubio-Briones J, López-Guerrero JA, Pineda-Lucena A. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics. 2017;13(5):52.